A Multi-Center, Prospective, Open Label, Single Arm Post Market Surveillance Study to Evaluate the Safety & Efficacy of Sterile, Non-Woven Pad Made of Soft-Adherent TLC-Ag Healing Matrix and Poly-Absorbent Fibres [Represented By Brand Name: UrgoClean Ag] in the Management of Diabetic Foot Ulcers

Eucare Pharmaceuticals Private Limited0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1.Male/ female patient Ë?18 years and Ë? 100 years
•2.Patient who can and willing to provide written Informed Consent
•3.Patient who has Diabetic foot ulcers which the investigator decides to employ UrgoClean Ag
•4.Patient who understands and is willing to participate in the clinical study and can comply with regular treatment visits and the follow-up regimen

•1. Patient with known allergy/hypersensitivity to silver or any of the dressing component
•2. Patient having a medical or social condition that would, in the opinion of the investigator, place the patient at an unacceptable risk or render the patient unable to meet the requirements of the protocol
•3. Patient with Severe lower limb ischemia (WIFI Classification 2 and 3), severe hepatic insufficiency, on renal dialysis, systemic steroid treatment, chemotherapy, immunodeficiency
•WIFI Classification (Society for Vascular Surgery)
•GradeABIAnkle systolic pressureTP, TcPO 2
•0>=0.80 >100 mm Hg>=60 mm Hg
•10.6-0.7970-100 mm Hg40-59 mm Hg
•20.4-0.5950-70 mm Hg30-39 mm Hg
•3<=0.39 <50 mm Hg <30 mm Hg
•4. Patient has participated in another clinical study involving another investigational agent within 4 weeks of the start of this trial, or is planning participation in another clinical trial during the current study duration
•5. Patients treated with wound dressings that include growth factors, bioengineered tissues, or skin substitutes other than the study material, within 30 days of the screening visit and throughout the study

发起方